Latest news with #Livshits
Yahoo
28-05-2025
- Business
- Yahoo
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an acute systemic infection. Needham analyst Gil Blum downgraded Rocket Pharmaceuticals from Buy to Hold, with a Nil price forecast from $42 earlier. The analyst cited increased uncertainty around the company's main value driver as the key reason for the downgrade.'We continue to have a favorable view of RP-A501's efficacy; however, we see increased uncertainty for the product given safety concerns,' Blum said in an analyst note. Blum anticipates limited readthrough to Rocket's other AAV programs, which utilize simpler immunosuppression regimens. Chardan Research analyst Geulah Livshits also lowered its price target from $46 to $17 while maintaining the Buy rating. While the disclosure does not negate the benefit reported for the program, the patient death and commentary regarding instances of TMA impact the benefit/risk profile of RP-A501, Livshits said in an analyst note. Livshits reduced the probability of success from 70% to 40%, given CBER leadership's focus on benefit/risk, pending more details regarding agency feedback and next steps. The analyst projects a slower uptake among the Danon population (3.6% by 2030E), assuming greater caution among prescribers. Chardan notes the company hasn't revealed how many patients have been treated in the trial so far but said the study is currently over-enrolled, with more patients ready to begin treatment. Management mentioned several possible next steps, such as switching to a simpler immunomodulatory treatment, using existing complement inhibitors known to be safe, and continuing to exclude patients who are genetically predisposed to complement activation. Chardan highlights that it's still unclear whether other immunomodulatory treatments could reduce the risk of TMA. There's no timeline for when the company might align with the FDA and restart the trial. Additional changes like enrolling more patients may be required, which could cause further delays. Given this uncertainty, the topline results are expected to come later than the previously guided mid-2026 timeframe. Other analyst reactions: Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5. Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform, lowering the price target from $37 to $8. Scotiabank maintains Rocket Pharmaceuticals with a Sector Outperform, lowering the price target from $51 to $19. Price Action: RCKT stock is trading higher by 6.44% to $2.48 at last check Wednesday. Read Next:Image via Shutterstock Date Firm Action From To Feb 2022 SVB Leerink Maintains Outperform Dec 2021 Chardan Capital Maintains Buy Aug 2021 SVB Leerink Maintains Outperform View More Analyst Ratings for RCKT View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Business Insider
15-05-2025
- Business
- Business Insider
Chardan Capital Reaffirms Their Buy Rating on Passage Bio (PASG)
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Passage Bio (PASG – Research Report), with a price target of $6.00. The company's shares closed yesterday at $0.27. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Livshits is a 5-star analyst with an average return of 16.2% and a 37.68% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Solid Biosciences, and Passage Bio. Passage Bio has an analyst consensus of Strong Buy, with a price target consensus of $7.33. Based on Passage Bio's latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.41 million. In comparison, last year the company had a GAAP net loss of $16.71 million Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PASG in relation to earlier this year. Last month, Orbimed Advisors Llc, a Major Shareholder at PASG sold 149,054.00 shares for a total of $49,704.12.
